2021
Contemporary practice patterns of tyrosine kinase inhibitor use among older patients with chronic myeloid leukemia in the United States
Shallis RM, Wang R, Bewersdorf JP, Zeidan AM, Davidoff AJ, Huntington SF, Podoltsev NA, Ma X. Contemporary practice patterns of tyrosine kinase inhibitor use among older patients with chronic myeloid leukemia in the United States. Therapeutic Advances In Hematology 2021, 12: 20406207211043404. PMID: 35154624, PMCID: PMC8832334, DOI: 10.1177/20406207211043404.Peer-Reviewed Original ResearchChronic phase chronic myeloid leukemiaFrontline tyrosine kinase inhibitorsTyrosine kinase inhibitorsOlder patientsChronic myeloid leukemiaTKI switchingMyeloid leukemiaSecond-generation tyrosine kinase inhibitorsBCR-ABL1 tyrosine kinase inhibitorsTyrosine kinase inhibitor useOlder CML patientsEnd Results-MedicareFavorable safety profileSpecific patient populationsContemporary practice patternsFrontline imatinibTKI choiceGreater comorbidityMost patientsInhibitor usePatient characteristicsWhite patientsDiagnosis yearTKI useCML patients
2017
Mechanisms of Hypercalcemia in Non-Hodgkin Lymphoma and Associated Outcomes: A Retrospective Review
Shallis RM, Rome RS, Reagan JL. Mechanisms of Hypercalcemia in Non-Hodgkin Lymphoma and Associated Outcomes: A Retrospective Review. Clinical Lymphoma Myeloma & Leukemia 2017, 18: e123-e129. PMID: 29361495, DOI: 10.1016/j.clml.2017.12.006.Peer-Reviewed Original ResearchConceptsNon-Hodgkin lymphomaDiffuse large B-cell lymphomaLarge B-cell lymphomaEtiology of hypercalcemiaB-cell lymphomaSerum calcitriolOverall survivalRetrospective reviewSingle-center retrospective reviewWorse progression-free survivalDiagnosis of NHLCalcitriol-mediated hypercalcemiaElevation of PTHrP.Episodes of hypercalcemiaNongerminal center subtypeProgression-free survivalMechanism of hypercalcemiaHigh-grade lymphomaCalcitriol levelsSerum PTHrPAdvanced diseaseMost patientsNHL patientsSerum levelsMedical records